Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

11/23/2022
AcquisitionsBreakingCataractDealsSurgical
Sightpath Acquires Accusite to Expand Mobile Footprint
Sightpath Acquires Accusite to Expand Mobile Footprint

Sightpath Medical, of Bloomington, Minnesota, announced Nov. 21 that it had acquired another mobile cataract surgery equipment provider, Accusite Surgical. No financial details were provided. Sight...

11/23/2022
BreakingClinical TrialGene TherapyRetina
Editas Pauses CRISPR/Cas9 Gene Therapy Trial for LCA10 Due to Disappointing Results
Editas Pauses CRISPR/Cas9 Gene Therapy Trial for LCA10 Due to Disappointing Results

Editas Medicine of Cambridge, Massachusetts, reported Nov. 17 that it would pause enrollment in its Phase I/II BRILLIANCE trial of EDIT-101 for the treatment of Leber congenital amaurosis 10 (LCA10...

11/23/2022
BreakingRegulationRetina
US FDA Accepts Apellis’ NDA Amendment for Pegcetacoplan in GA; Iveric’s Zimura Granted Breakthrough Status
US FDA Accepts Apellis’ NDA Amendment for Pegcetacoplan in GA; Iveric’s Zimura Granted Breakthrough Status

Apellis announced Nov. 18 that the US FDA had accepted its amended new drug application (NDA) in geographic atrophy (GA) for pegcetacoplan, a complement C3 inhibitor, with 24-month efficacy data fr...

11/21/2022
CataractIOLNewsletterPremium
Improved PC-IOL Technology is Key to Recent and Future Premium Cataract Surgery Growth
Improved PC-IOL Technology is Key to Recent and Future Premium Cataract Surgery Growth

Presbyopia-correcting IOL technology improvements have led to almost a doubling of global units over the past five years and will be critical to driving future growth over the next five years. In 2...

11/23/2022
BreakingRefractiveSurgical
STAAR Surgical Opens First EVO Experience Center in US
STAAR Surgical Opens First EVO Experience Center in US

STAAR Surgical reported Nov. 21 that it had opened the first US-based EVO Experience Center, located at the company’s headquarters in Lake Forest, California. STAAR said the center is similar to EV...

11/23/2022
BreakingGenericsGlaucoma
Prasco Launches Authorized Generic of Zioptan (Tafluprost) Drops for Glaucoma
Prasco Launches Authorized Generic of Zioptan (Tafluprost) Drops for Glaucoma

Prasco Laboratories announced Nov. 18 that it had launched an authorized generic version of Zioptan (tafluprost ophthalmic solution) 0.0015% for glaucoma. Prasco, of Mason, Ohio, said it was its fi...

11/23/2022
BreakingClinical TrialDry EyeRegulation
OKYO Files IND with US FDA for Phase II Trial of Dry Eye Candidate
OKYO Files IND with US FDA for Phase II Trial of Dry Eye Candidate

London’s OKYO Pharma announced Nov. 21 that it had filed an investigational new drug (IND) application with the US FDA for its topical dry eye treatment candidateOK-101. The company said it had des...

11/21/2022
Dry EyeNewsletter
New Products Shake Up Dry Eye Market, Pressure Leaders
New Products Shake Up Dry Eye Market, Pressure Leaders

New products are changing the landscape of dry eye treatment. Longtime favorites face competition from less expensive alternatives on one side and more specialized treatments on the other. Perennia...

11/21/2022
AcquisitionsNewsletterPharma
Viatris to Acquire Oyster Point and India-Based Famy Life Sciences for $705 Million
Viatris to Acquire Oyster Point and India-Based Famy Life Sciences for $705 Million

Viatris put the ophthalmology business world on notice on Nov. 7 with a major step toward its goal of becoming “the next global ophthalmology leader.” The Pittsburgh company announced a $705 millio...

11/21/2022
NewsletterRegulation
CMS Cuts Physician Payments for 2023, Rejects Non-facility Price for Nominated Ophthalmic Surgeries
CMS Cuts Physician Payments for 2023, Rejects Non-facility Price for Nominated Ophthalmic Surgeries

The final 2023 Medicare Physician Fee Schedule will implement cuts to surgeon reimbursement close to the rates proposed in July. Surgeon reimbursement for noncomplex cataract surgery (CPT code 6698...

11/21/2022
NewsletterRegulationRetina
Race for First US-Approved GA Therapy Tightens between Iveric Bio and Apellis
Race for First US-Approved GA Therapy Tightens between Iveric Bio and Apellis

The race for the first approved geographic atrophy (GA) treatment in the US heated up in November as Iveric Bio got closer to the regulatory finish line—and Apellis got a bit farther away. Iveric B...

11/21/2022
DealsFundingNewsletter
Omeros Leads Latest Ophthalmic Fundraising with $125 Million Royalty Sale
Omeros Leads Latest Ophthalmic Fundraising with $125 Million Royalty Sale

Seattle-based Omeros led recent ophthalmic fundraising efforts, raising $125 million through the sale of a portion of future royalties to DRI Healthcare. Funding announced in the past four weeks to...

Past News Stories

11/21/2022
DiagnosticLaserNewsletterRegulation
Select US FDA Approvals and Clearances in October 2022
Select US FDA Approvals and Clearances in October 2022

The US FDA granted four clearances through the ophthalmic device division using the 510(k) pathway in October 2022, according to the agency’s database. Notably, Norlase gained clearance for its Ech...

11/21/2022
NewsletterRegulationRetina
US FDA Accepts Outlook’s Resubmitted BLA for Lytenava in Wet AMD
US FDA Accepts Outlook’s Resubmitted BLA for Lytenava in Wet AMD

Outlook Therapeutics reported Oct. 28 that the US FDA had accepted the resubmitted biologics license application (BLA) for Outlook’s ophthalmic bevacizumab candidate ONS-5010 in wet age-related mac...

11/21/2022
Clinical TrialNewsletterPresbyopia
Novartis Drops Presbyopia Candidate UNR844 After Disappointing Trial Results
Novartis Drops Presbyopia Candidate UNR844 After Disappointing Trial Results

Swiss company Novartis reported Oct. 25 that it had dropped its program for presbyopia treatment candidate UNR844 after seeing disappointing interim results from its Phase IIb trial. In its Q3-2022...

11/21/2022
DealsIndustryInstrumentsNewsletterSurgical
Corza Partners with Vortex Surgical to Market Line of Vitreoretinal Instruments
Corza Partners with Vortex Surgical to Market Line of Vitreoretinal Instruments

Corza Medical announced Nov. 3 that it had formed a commercial partnership with Vortex Surgical to market Vortex’ line of vitreoretinal instruments. No financial details of the partnership were pro...

11/21/2022
IndustryNewsletterRetinaSurgical
Ophthalmic Market Totaled $42.5 Billion in 2021 as it Rebounded from Pandemic
Ophthalmic Market Totaled $42.5 Billion  in 2021 as it Rebounded from Pandemic

The ophthalmic industry has largely recovered from the pandemic-related slump and is back to more normal growth patterns. Market Scope expects the industry to grow at a combined annual growth rate ...

11/21/2022
NewsletterRetinaStudy
NEI Scientists Discover Essential Shape-Changing Step in Recharging of Retina’s Photoreceptors
NEI Scientists Discover Essential Shape-Changing Step in Recharging of Retina’s Photoreceptors

Scientists have discovered a mechanism by which an area of a protein shifts its shape to convert vitamin A into a form usable by photoreceptors in the retina. A previously uncharacterized area of t...

11/21/2022
NewsletterRetinaStudy
NEI Researchers Unravel Mechanism of Stargardt Disease in RPE
NEI Researchers Unravel Mechanism of Stargardt Disease in RPE

Researchers have found the first direct evidence of how Stargardt-related ABCA4 gene mutations affect the retinal pigment epithelium (RPE) using a new stem-cell based model made from human skin cel...

11/21/2022
CataractDry EyeGene TherapyGlaucomaMyopiaNewsletterPresbyopiaRetina
Clinical Trial Updates for Ophthalmic Candidates, November 2022
Clinical Trial Updates for Ophthalmic Candidates, November 2022

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements. Date Company Candidate, Indication Milestone Notes Nov. 8 MediPrint Ophthalmics LL-BMT1 (bim...

11/21/2022
NewsletterRefractiveSurgical
Team Wins 2022 Golden Goose Award for Contributions to Bladeless LASIK
Team Wins 2022 Golden Goose Award for Contributions to Bladeless LASIK

Five pioneers in the use of femtosecond lasers for ophthalmology have been honored with the Golden Goose Award from the American Association for the Advancement of Science (AAAS), the world’s large...

11/21/2022
CornealNewsletterSurgical
€1 Million Vision Award Goes to Two Leaders in Research, Treatment of Corneal Disease
€1 Million Vision Award Goes to Two Leaders in Research, Treatment of Corneal Disease

Two physician-scientists who are leaders in the research and treatment of corneal disease have been honored with a €1 million vision award by Portugal’s Champalimaud Foundation, the group announced...

11/21/2022
CornealIndustryNewsletter
Aurion Biotech Wins Prix Galien Startup Award for Innovations in Corneal Cell Therapy
Aurion Biotech Wins Prix Galien Startup Award for Innovations in Corneal Cell Therapy

Aurion Biotech, which is developing a corneal endothelial cell therapy, announced Oct. 27 that it had won the Prix Galien Award for Best Startup in Biotech/Pharma. The Galien Foundation, of New Yor...

11/21/2022
NewsletterRefractiveSurgical
Weekly Surgeon Poll, November 2022
Weekly Surgeon Poll, November 2022

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more